As COVID-19 continues to change the clinical trial landscape, innovations in site and patient engagements will help determine the success of oncology trials.
Join us for our upcoming webinar with Dr. Ari VanderWalde, a member of George Clinical’s scientific leadership team with oncology clinical research expertise, May 27th.
This webcast will give the oncology community an in-depth understanding of preparing safe and efficient trials and implementing best practices to mitigate disruption during COVID-19 restrictions.
Topics covered in this webinar include:
The session will be streamed live on: May 27, 11:00 am USA CDT
Dr. VanderWalde’s primary research is in melanoma, immunotherapy and targeted therapies based on immune markers and aberrations in cancer genetics. He is Vice President of Clinical Development, Caris Life Sciences, and Senior Medical Director, George Clinical. A thought leader in melanoma and clinical trial design and implementation, he has collaborated on advisory boards with many of the nation’s thought leaders and top experts in the field and previously served as United States Medical Lead and Clinical Research Medical Director with Amgen Inc., directing U.S. global development of talimogene laherparepvec, a novel viral-based immunotherapeutic that has shown efficacy in late-stage clinical trials in melanoma.
As Former Director of Research at West Cancer Center and Research Institute, Dr. VanderWalde was responsible for managing the portfolio of all clinical trials. He is the former Director of Precision Oncology at OneOncology.
Meet with George Clinical! Contact us to schedule a time now.